| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | lytA |
| Uniprot No | P24556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-481aa |
| 氨基酸序列 | MQAKLTKNEFIERLKTSEGKQFNVDLWYGFQCFDYANAGWKVLFGLLLKGLGAKDIPFANNFDGLATVYQNTPDFLAQPGDMVVFGSNYGAGYGHVAWVIEATLDYIIVYEQNWLGGGWTDGIEQPAGVGKKLQDDNMLMISLCGLSVRILKVRQRHDQFNLLHKHPKKETAKPQPKAVELKIIKDVVKGYDLPKRGSNPKGIVIHNDAGSKGATAEAYRNGLVNAPLSRLEAGIAHSYVSGNTVWQALDESQVGWHTANQIGNKYYYGIEVCQSMGADNATFLKNEQATFQECARLLKKWGLPANRNTIRLHNEFTSTSCPHRSSVLHTGFDPVTRGLLPEDKRLQLKDYFIKQIRAYMDGKIPVATVSNESSASSNTVKPVASAWKRNKYGTYYMEESARFTNGNQPITVRKVGPFLSCPVGYQFQPGGYCDYTEVMLQDGHVWVGYTWEGQRYYLPIRTWNGSAPPNQILGDLWGEIS |
| 预测分子量 | 57.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于lytA重组蛋白的3篇参考文献及其摘要概要：
---
1. **文献名称**：*"Molecular characterization of the pneumococcal lytA gene responsible for autolysis"*
**作者**：Croux, C., et al. (1990)
**摘要**：该研究克隆并表达了肺炎链球菌的lytA基因于大肠杆菌中，证实重组lytA蛋白具有依赖于胆碱的自溶酶活性，并分析了其结构功能关系，为后续酶学应用奠定基础。
2. **文献名称**：*"Immunization with recombinant Streptococcus pneumoniae neuraminidase NanA and LytA proteins in a murine model"*
**作者**：Briles, D.E., et al. (2000)
**摘要**：通过在小鼠模型中评估重组lytA与NanA蛋白的联合免疫效果，发现两者可诱导特异性抗体并增强对肺炎链球菌感染的防护，提示其作为疫苗组分的潜力。
3. **文献名称**：*"Purification and evaluation of a recombinant fragment of pneumococcal autolysin (lytA) as a species-specific antigen for immunodiagnosis"*
**作者**：Mendoza-Hernández, G., et al. (2003)
**摘要**：研究报道了重组lytA蛋白的高效纯化，并验证其作为肺炎链球菌特异性抗原用于ELISA检测，显著提升临床样本诊断的特异性与灵敏度。
---
以上文献聚焦于lytA重组蛋白的表达、疫苗开发及诊断应用，反映了其在基础研究与转化医学中的多重价值。
LytA is a major autolysin protein derived from *Streptococcus pneumoniae*, a pathogenic bacterium responsible for pneumococcal infections. As a member of the N-acetylmuramoyl-L-alanine amidase family, LytA plays a critical role in bacterial cell wall remodeling, daughter cell separation, and programmed autolysis. Structurally, it contains a conserved choline-binding domain (CBD) at the C-terminus and a catalytic domain (CHAP domain) at the N-terminus. The CBD mediates attachment to choline residues in pneumococcal teichoic acids, while the CHAP domain hydrolyzes peptidoglycan bonds, enabling cell lysis under stress or during stationary phase.
Recombinant LytA (rLytA) is produced through heterologous expression systems, such as *E. coli*, enabling large-scale purification for research and applications. Its choline-dependent lytic activity and species specificity make it a valuable tool in pneumococcal detection assays, including rapid diagnostic tests and bacterial lysis protocols. Additionally, rLytA is studied for vaccine development, either as a protein antigen or carrier for polysaccharide conjugates, leveraging its immunogenic properties.
Beyond diagnostics and vaccinology, rLytA serves as a model protein for studying cell wall dynamics, autolysis regulation, and host-pathogen interactions. Recent studies also explore its potential in biotechnology, such as enzymatic cell disruption for protein extraction. However, its role in antibiotic-induced lysis (e.g., β-lactams) underscores its clinical relevance in understanding treatment efficacy and bacterial resistance mechanisms. Overall, rLytA’s versatility bridges basic microbiology and applied biomedical research.
×
